Patent Application: Intrathecal T regulatory cells for Multiple Sclerosis Treatment
Summary
The USPTO has published a patent application (US20260083664A1) for a medicinal product involving intrathecal administration of T regulatory cells for treating multiple sclerosis. The application was filed on December 3, 2025, by inventors Piotr Trzonkowski and Kamil Chwojnicki.
What changed
This document is a published patent application from the USPTO detailing a novel treatment for multiple sclerosis. The application, US20260083664A1, describes a medicinal product comprising specific T regulatory cells (CD3+CD4+CD25+CD127−) administered intrathecally.
While this is a patent application and not a regulatory rule, it signifies potential future developments in pharmaceutical treatments. Companies in the pharmaceutical and biotechnology sectors involved in neurology or immunology research may find this application of interest for competitive intelligence or potential licensing opportunities. No immediate compliance actions are required for regulated entities based on this filing.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INTRATHECAL ADMINISTRATION OF T REGULATORY CELLS IN THE TREATMENT OF MULTIPLE SCLEROSIS
Application US20260083664A1 Kind: A1 Mar 26, 2026
Inventors
Piotr TRZONKOWSKI, Kamil CHWOJNICKI
Abstract
The invention relates to the medicinal product consisting of CD3+CD4+CD25+CD127− T regulatory cells administered intrathecally in the treatment of multiple sclerosis.
CPC Classifications
A61K 9/0019 A61K 40/11 A61K 40/22 A61K 40/416 A61P 25/00 C12N 5/0637 A61K 2239/31
Filing Date
2025-12-03
Application No.
19407506
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.